Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.41 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23809486 | 0.90 | MEN1 (0.50) | KDM4EMEN1KMT2AGAAALDH1A1 | |
| SCHEMBL23809228 | 0.84 | KDM4E (0.43) | KDM4EALDH1A1 | |
| SCHEMBL23809271 | 0.81 | KDM4E (0.41) | KDM4EHTTPOLBALDH1A1 | |
| SCHEMBL26037572 | 0.80 | HRH3 (0.39) | KDM4EMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL23809100 | 0.80 | KDM4E (0.39) | KDM4EALDH1A1 | |
| SCHEMBL23809525 | 0.79 | HRH3 (0.41) | KDM4EMEN1KMT2AL3MBTL1POLB | |
| SCHEMBL23809290 | 0.78 | KDM4E (0.54) | KDM4EL3MBTL1GAAALDH1A1 | |
| SCHEMBL23809487 | 0.77 | MCL1 (0.38) | KDM4EALDH1A1 | |
| SCHEMBL26581441 | 0.76 | KDM4E (0.52) | KDM4EMEN1KMT2APOLBGAA | |
| SCHEMBL26037542 | 0.75 | SMN1; SMN2 (0.48) | KDM4EMEN1KMT2APSMB1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | KDM4E 1156/4885MEN1 3549/4885KMT2A 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.